FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Roy Larsen

Research Profile

Chemicals & Drugs

Objects

Alpha Particles

Living Beings

Procedures

Concepts & Ideas

Anatomy

Disorders

Bone Neoplasms

Co-author Network

Publications

TOP 3
Ada H V Repetto-Llamazares; Roy H Larsen; Michael Lassmann; Camilla Mollatt; Jostein Dahle
Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma.
Jostein Dahle; Arne Kolstad; Katrine B Melhus; Camilla S Mollatt; Ada H V Repetto-Llamazares; Oyvind S Bruland; Roy H Larsen
Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.
Jostein Dahle; Thora Johanna Jonasdottir; Helen Heyerdahl; Jahn M Nesland; Jorgen Borrebaek; Anne Kristine Hjelmerud; Roy H Larsen
Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Roy Larsen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Ada H V Repetto-Llamazares; Roy H Larsen; Michael Lassmann; Camilla Mollatt; Jostein Dahle
Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma.
Current radiopharmaceuticals 2013;6(1):20-7.
2013: Jostein Dahle; Arne Kolstad; Katrine B Melhus; Camilla S Mollatt; Ada H V Repetto-Llamazares; Oyvind S Bruland; Roy H Larsen
Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.
Anticancer research 2013;33(1):85-95.
2010: Jostein Dahle; Thora Johanna Jonasdottir; Helen Heyerdahl; Jahn M Nesland; Jorgen Borrebaek; Anne Kristine Hjelmerud; Roy H Larsen
Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab.
European journal of nuclear medicine and molecular imaging 2010;37(1):93-102.
2009: Jostein Dahle; Cecilie Krogh; Katrine B Melhus; Jorgen Borrebaek; Roy H Larsen; Yngve Kvinnsland
In vitro cytotoxicity of low-dose-rate radioimmunotherapy by the alpha-emitting radioimmunoconjugate Thorium-227-DOTA-rituximab.
International journal of radiation oncology, biology, physics 2009;75(3):886-95.
2008: Jostein Dahle; Oyvind S Bruland; Roy H Larsen
Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.
International journal of radiation oncology, biology, physics 2008;72(1):186-92.
2007: Jostein Dahle; Jorgen Borrebaek; Thora Johanna Jonasdottir; Anne Kristine Hjelmerud; Katrine B Melhus; Øyvind S Bruland; Oliver W Press; Roy H Larsen
Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate.
Blood 2007;110(6):2049-56.
2007: Jostein Dahle; Cecilie Krogh; Katrine B Melhus; Olav Kaalhus; Roy H Larsen; Trond Stokke
A one-step method for determining the maximum number of bound antibodies, and the affinity and association rate constants for antibody binding.
Nuclear medicine communications 2007;28(9):742-7.
2007: Katrine B Melhus; Roy H Larsen; Trond Stokke; Olav Kaalhus; Pål Kristian Selbo; Jostein Dahle
Evaluation of the binding of radiolabeled rituximab to CD20-positive lymphoma cells: an in vitro feasibility study concerning low-dose-rate radioimmunotherapy with the alpha-emitter 227Th.
Cancer biotherapy & radiopharmaceuticals 2007;22(4):469-79.
2007: Roy H Larsen; Jorgen Borrebaek; Jostein Dahle; Katrine B Melhus; Cecilie Krogh; Miriam H Valan; Oyvind S Bruland
Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability.
Cancer biotherapy & radiopharmaceuticals 2007;22(3):431-7.
2006: Øyvind S Bruland; Sten Nilsson; Darrell R Fisher; Roy H Larsen
High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 2):6250s-6257s.
2006: Thora Johanna Jonasdottir; Darrell R Fisher; Jorgen Borrebaek; Oyvind S Bruland; Roy H Larsen
First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent.
Anticancer research 2006;26(4B):2841-8.
2006: Roy H Larsen; Henrik Saxtorph; Mikala Skydsgaard; Jorgen Borrebaek; Thora Johanna Jonasdottir; Oyvind S Bruland; Signe Klastrup; Robert Harling; Thomas Ramdahl
Radiotoxicity of the alpha-emitting bone-seeker 223Ra injected intravenously into mice: histology, clinical chemistry and hematology.
In vivo (Athens, Greece) 2006;20(3):325-31.
2006: Jostein Dahle; Jorgen Borrebaek; Katrine B Melhus; Oyvind S Bruland; Gro Salberg; Dag Rune Olsen; Roy H Larsen
Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy.
Nuclear medicine and biology 2006;33(2):271-9.
2005: Sten Nilsson; Roy H Larsen; Sophie D Fosså; Lise Balteskard; Kari W Borch; Jan-Erik Westlin; Gro Salberg; Oyvind S Bruland
First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4451-9.
2005: Gjermund Henriksen; Oyvind S Bruland; Roy H Larsen
Preparation and preclinical assessment of folate-conjugated, radiolabelled antibodies.
Anticancer research 2005;25(1A):9-15.
2004: Gjermund Henriksen; B W Schoultz; T E Michaelsen; Øyvind S Bruland; Roy H Larsen
Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides.
Nuclear medicine and biology 2004;31(4):441-9.
2004: Gjermund Henriksen; Oyvind S Bruland; Roy H Larsen
Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents.
Anticancer research 2004;24(1):101-5.
2003: Gjermund Henriksen; Darrell R Fisher; John Roeske; Øyvind S Bruland; Roy H Larsen
Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(2):252-9.
2002: Gjermund Henriksen; Knut Breistøl; Øyvind S Bruland; Øystein Fodstad; Roy H Larsen
Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model.
Cancer research 2002;62(11):3120-5.
2002: Gjermund Henriksen; Per Hoff; Roy H Larsen
Evaluation of potential chelating agents for radium.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2002;56(5):667-71.
2002: Ellen Aurlien; Yngve Kvinnsland; Roy H Larsen; Øyvind S Bruland
Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation.
International journal of radiation biology 2002;78(2):133-42.
2001: Gjermund Henriksen; S Messelt; E Olsen; Roy H Larsen
Optimisation of cyclotron production parameters for the 209Bi(alpha, 2n) 211At reaction related to biomedical use of 211At.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2001;54(5):839-44.
2000: Ellen Aurlien; Roy H Larsen; Gunnar Kvalheim; Oyvind S Bruland
Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells.
British journal of cancer 2000;83(10):1375-9.
2000: Ellen Aurlien; Roy H Larsen; Gamal Akabani; Dag Rune Olsen; M R Zalutsky; Oyvind S Bruland
Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry.
International journal of radiation biology 2000;76(8):1129-41.
1999: KM Murud; Roy H Larsen; Oyvind S Bruland; Per Hoff
Influence of pretreatment with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APB) on organ uptake of 211At and 125I-labeled amidobisphosphonates in mice.
Nuclear medicine and biology 1999;26(7):791-4.
1999: Roger E McLendon; Gary E Archer; Roy H Larsen; Gamal Akabani; Darell D Bigner; Michael R Zalutsky
Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis.
International journal of radiation oncology, biology, physics 1999;45(2):491-9.
1999: Roy H Larsen; KM Murud; Gamal Akabani; Per Hoff; Oyvind S Bruland; M R Zalutsky
211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(7):1197-203.
1999: KM Murud; Roy H Larsen; Per Hoff; M R Zalutsky
Synthesis, purification, and in vitro stability of 211At- and 125I-labeled amidobisphosphonates.
Nuclear medicine and biology 1999;26(4):397-403.
1998: Roy H Larsen; SK Slade; Michael R Zalutsky
Blocking [211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds.
Nuclear medicine and biology 1998;25(4):351-7.
1998: Roy H Larsen; Oyvind S Bruland
Intratumour injection of immunoglobulins labelled with the alpha-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay.
British journal of cancer 1998;77(7):1115-22.
1998: Marlene L Hauck; Roy H Larsen; Philip Welsh; Michael R Zalutsky
Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia.
British journal of cancer 1998;77(5):753-9.
1998: Roy H Larsen; Gamal Akabani; Philip Welsh; Michael R Zalutsky
The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.
Radiation research 1998;149(2):155-62.
1997: Roy H Larsen; Ganesan Vaidyanathan; Michael R Zalutsky
Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells.
International journal of radiation biology 1997;72(1):79-90.
1997: Michael R Zalutsky; M G Stabin; Roy H Larsen; Darell D Bigner
Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate.
Nuclear medicine and biology 1997;24(3):255-61.
1997: Ganesan Vaidyanathan; Xiao-Guang Zhao; Roy H Larsen; Michael R Zalutsky
3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
British journal of cancer 1997;76(2):226-33.
1996: Ganesan Vaidyanathan; Roy H Larsen; Michael R Zalutsky
5-[211 At]astato-2'-deoxyuridine, an alpha particle-emitting endoradiotherapeutic agent undergoing DNA incorporation.
Cancer research 1996;56(6):1204-9.
1996: Roy H Larsen; B W Wieland; Michael R Zalutsky
Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (alpha,2n)211 at reaction.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 1996;47(2):135-43.
1995: Roy H Larsen; Per Hoff; I B Vergote; Oyvind S Bruland; Magne Aas; L De Vos; Kjell Nustad
Alpha-particle radiotherapy with 211At-labeled monodisperse polymer particles, 211At-labeled IgG proteins, and free 211At in a murine intraperitoneal tumor model.
Gynecologic oncology 1995;57(1):9-15.
1994: Roy H Larsen; Oyvind S Bruland; Per Hoff; J Alstad; T Lindmo; E K Rofstad
Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody: comparison with astatine-211-labeled bovine serum albumin, free astatine-211 and external-beam X rays.
Radiation research 1994;139(2):178-84.
1994: Roy H Larsen; Oyvind S Bruland; Per Hoff; J Alstad; E K Rofstad
Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody.
British journal of cancer 1994;69(6):1000-5.
1992: I Vergote; Roy H Larsen; L de Vos; Jahn M Nesland; Oyvind S Bruland; J Bjørgum; J Alstad; Claes Tropé; Kjell Nustad
Therapeutic efficacy of the alpha-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor model.
Gynecologic oncology 1992;47(3):366-72.
1992: I Vergote; Roy H Larsen; L De Vos; Mette Winderen; T Ellingsen; J Bjørgum; Per Hoff; Magne Aas; Claes Tropé; Kjell Nustad
Distribution of intraperitoneally injected microspheres labeled with the alpha-emitter astatine (211At) compared with phosphorus (32P) and yttrium (90Y) colloids in mice.
Gynecologic oncology 1992;47(3):358-65.